이 애플리케이션의 일부 콘텐츠는 현재 사용할 수 없습니다.
이 상황이 계속되면 다음 주소로 문의하십시오피드백 및 연락
1. (WO2019067413) USE OF FENFLURAMINE FORMULATION IN REDUCING NUMBER AND FREQUENCIES OF CONVULSIVE SEIZURES IN PATIENT POPULATIONS
국제사무국에 기록된 최신 서지정보정보 제출

공개번호: WO/2019/067413 국제출원번호: PCT/US2018/052580
공개일: 04.04.2019 국제출원일: 25.09.2018
IPC:
A61K 31/137 (2006.01) ,A61P 25/08 (2006.01) ,A61K 45/06 (2006.01)
A SECTION A — 생활필수품 농업
61
위생학; 의학 또는 수의학
K
의약용, 치과용 또는 화장용 제제
31
유기 활성 성분을 함유 하는 의약품 제재
13
아민, 예. 아만타딘
135
방향족환을 가지는 것, 예. 메타돈
137
아릴알킬아민, 예. 암페타민, 에피네프린, 살부타몰, 에페드린
A SECTION A — 생활필수품 농업
61
위생학; 의학 또는 수의학
P
화합물 또는 의약품 제제의 특정한 치료효과
25
신경계질환 의약
08
항간질제; 항발작제
A SECTION A — 생활필수품 농업
61
위생학; 의학 또는 수의학
K
의약용, 치과용 또는 화장용 제제
45
A61K 31/00에서 A61K 41/00사이의 그룹에 속하지 않는 활성성분을 함유하는 의약품 제제
06
화학적 특성을 갖지 않는 활성성분의 혼합물, 예. 소염제 및 강필제
출원인:
ZOGENIX INTERNATIONAL LIMITED [GB/GB]; Siena Court Broadway Maidenhead Berkshire SL6 1NJ, GB
FARFEL, Gail [US/US]; US
LOCK, Michael [US/US]; US
GALER, Bradley S. [US/US]; US
MORRISON, Glenn [CA/US]; US
BOYD, Brooks M. [US/US]; US
발명자:
FARFEL, Gail; US
LOCK, Michael; US
GALER, Bradley S.; US
MORRISON, Glenn; US
BOYD, Brooks M.; US
대리인:
BOZICEVIC, Karl; US
우선권 정보:
16/139,60824.09.2018US
16/139,61724.09.2018US
16/139,69824.09.2018US
16/139,70124.09.2018US
16/139,70424.09.2018US
16/139,76324.09.2018US
62/563,25526.09.2017US
62/564,22527.09.2017US
62/579,45031.10.2017US
62/593,02930.11.2017US
62/627,32907.02.2018US
62/669,83310.05.2018US
62/696,80111.07.2018US
발명의 명칭: (EN) USE OF FENFLURAMINE FORMULATION IN REDUCING NUMBER AND FREQUENCIES OF CONVULSIVE SEIZURES IN PATIENT POPULATIONS
(FR) UTILISATION D'UNE FORMULATION DE FENFLURAMINE POUR RÉDUIRE LE NOMBRE ET LES FRÉQUENCES DE CRISES CONVULSIVES DANS DES POPULATIONS DE PATIENTS
요약서:
(EN) A method of reducing convulsive seizure frequency in a human patient diagnosed with Dravet syndrome, comprising administering to the patient a therapeutically effective dose of fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, and repeating the administering over a period of days until the patient exhibits a significant reduction (e.g., 40% or greater) from baseline in convulsive seizure frequency. In some embodiments of the method, convulsive seizures are completely eliminated for 10 days or more, 20 days or more, 30 days or more, 50 days or more, 100 days or more.
(FR) L'invention concerne une méthode de réduction de la fréquence de crises convulsives chez un patient humain chez qui on a diagnostiqué le syndrome de Dravet, consistant à administrer au patient une dose thérapeutiquement efficace de fenfluramine ou d'un sel, d'une base, d'un acide ou d'une amine pharmaceutiquement acceptable de celle-ci, et à répéter l'administration pendant une période de jours jusqu'à ce que le patient présente une réduction significative (par exemple, au moins 40 %) par rapport à la ligne de base de la fréquence de crises convulsives. Dans certains modes de réalisation de la méthode, les crises convulsives sont complètement éliminées pendant au moins 10 jours, au moins 20 jours, au moins 30 jours, au moins 50 jours, au moins 100 jours.
front page image
지정국: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
아프리카지역 지식재산권기구(ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
유라시아 특허청(EAPO) (AM, AZ, BY, KG, KZ, RU, TJ, TM)
유럽 특허청(EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
아프리카 지식재산권기구(OAPI) (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
공개언어: 영어 (EN)
출원언어: 영어 (EN)